Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

Executive Summary

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

You may also be interested in...



Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.

Merck KGaA's MS Drug Mavenclad May Defy Doubters

The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel